US longevity lobbying group A4LI announces a shift to corporate membership starting in 2027
US longevity lobbying group A4LI announces a shift to corporate membership starting in 2027
On November 12, the organization invited biotechnology companies, clinics, and venture capital funds that invest in early-stage companies to join a coalition. Members are invited to work together to advocate for FDA reforms and government funding for aging research.
In its 2022 program, A4LI offered sponsorship opportunities to companies and investors, alongside several membership tiers for individual supporters. For 100 dollars a year, the alliance promised individual members a T-shirt and access to exclusive podcasts. In its new announcement, A4LI invites companies to present a “united industry front on Capitol Hill,” meaning the US Congress.
In July, A4LI reported on summit participants’ meetings with members of Congress. The alliance promises year-round representation in Congress for its corporate members. At monthly meetings, A4LI will brief them on the work of lawmakers and government agencies. During the alliance’s summit, two representatives from each company will be able to take part in meetings with lawmakers.
Companies can share their policy priorities with the alliance in a survey. They can select multiple areas, including reform of FDA procedures, research funding through the US National Institutes of Health, or other priorities.
A4LI proposes establishing a common process for reaching agreement on trials of drugs that target biological processes involved in several age-related diseases. These trials assess the risk of developing different diseases or of existing diseases worsening. According to the alliance, seeking agreement from separate FDA divisions, each responsible for its own group of diseases, duplicates work and leads to sequential reviews of different uses of the same drug.
Under A4LI’s proposal, a drug developer would agree on a trial plan and an overall analysis plan with a team drawn from multiple FDA divisions. The developer and FDA specialists would decide in advance which events to count, such as the onset or worsening of heart and kidney diseases, and how to combine them when assessing the drug’s effect.
- https://a4li.org/wp-content/uploads/2022/11/Membership-Updates-1.pdf
- https://x.com/theA4LI/status/2120924982050259221
- https://t.me/UkhvatNews/2252
- https://a4li.org/company-member/
- https://us20.list-manage.com/survey?u=f735b4997e11ef64ffafa9fd9&id=c431ac9125&attribution=false
- https://a4li.org/wp-content/uploads/2026/10/MDTD-with-PDUFA-VIII-Language-August-2026.pdf